Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has received a consensus recommendation of “Buy” from the twenty-four analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, ten have assigned a hold recommendation, twelve have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $131.42.

Several equities research analysts recently commented on ICPT shares. Goldman Sachs Group upgraded Intercept Pharmaceuticals from a “sell” rating to a “buy” rating and raised their target price for the company from $46.00 to $157.00 in a report on Monday, August 6th. Roth Capital started coverage on Intercept Pharmaceuticals in a report on Wednesday, September 12th. They set a “buy” rating and a $192.00 target price on the stock. BidaskClub upgraded Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, July 4th. ValuEngine downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 2nd. Finally, Zacks Investment Research upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $105.00 target price on the stock in a report on Tuesday, July 10th.

In other Intercept Pharmaceuticals news, insider David Shapiro sold 4,917 shares of Intercept Pharmaceuticals stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $111.43, for a total transaction of $547,901.31. Following the sale, the insider now directly owns 42,196 shares in the company, valued at approximately $4,701,900.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.90% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the business. Swiss National Bank increased its holdings in shares of Intercept Pharmaceuticals by 4.5% in the 1st quarter. Swiss National Bank now owns 30,500 shares of the biopharmaceutical company’s stock valued at $1,876,000 after acquiring an additional 1,300 shares during the last quarter. Schwab Charles Investment Management Inc. increased its holdings in shares of Intercept Pharmaceuticals by 18.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 54,249 shares of the biopharmaceutical company’s stock valued at $3,338,000 after acquiring an additional 8,471 shares during the last quarter. Aperio Group LLC bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter valued at approximately $316,000. US Bancorp DE increased its holdings in shares of Intercept Pharmaceuticals by 821.6% in the 1st quarter. US Bancorp DE now owns 1,751 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 1,561 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Intercept Pharmaceuticals by 2.9% in the 1st quarter. Northern Trust Corp now owns 88,800 shares of the biopharmaceutical company’s stock valued at $5,463,000 after acquiring an additional 2,489 shares during the last quarter. Institutional investors own 69.38% of the company’s stock.

Shares of NASDAQ:ICPT traded up $2.38 during mid-day trading on Friday, hitting $120.03. 857 shares of the company traded hands, compared to its average volume of 325,023. The company has a market cap of $3.38 billion, a P/E ratio of -8.32 and a beta of -1.73. The company has a debt-to-equity ratio of 2.48, a quick ratio of 6.51 and a current ratio of 6.51. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $124.40.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) EPS for the quarter, beating the consensus estimate of ($2.83) by $0.25. The business had revenue of $43.58 million for the quarter, compared to the consensus estimate of $41.26 million. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The company’s revenue was up 41.1% on a year-over-year basis. During the same period last year, the business posted ($3.46) EPS. analysts predict that Intercept Pharmaceuticals will post -10.83 earnings per share for the current year.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).

Featured Story: Do closed-end mutual funds pay dividends?

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.